May 14, 2020 / 5:24 AM / 13 days ago

BRIEF-Relief Therapeutics Announces With Neurorx Final Manufacturing Validation Of RLF-100 For Phase 2B/3 Clinical Trial

May 14 (Reuters) - RELIEF THERAPEUTICS HOLDING SA:

* ANNOUNCES WITH NEURORX FINAL MANUFACTURING VALIDATION OF RLF-100 FOR PHASE 2B/3 CLINICAL TRIAL IN PATIENTS WITH COVID-19 ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME Source text: bit.ly/3cvaLof Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below